OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 2,916 JAZZ derivative securities | OQRO

Home
Insider trades
Jazz Pharmaceuticals
Officer exercised or converted 2,916 JAZZ derivative securities

Insider trades

Insider trade

Officer exercised or converted 2,916 JAZZ derivative securities

Traded Aug 27, 2026 · Filed Sep 1, 2026

JAZJazz PharmaceuticalsJAZZ

2,916
Shares · @ $137.12

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 27, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 1, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001737329-26-000016

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Sep 1, 2026, 2:45 AM UTC

Added to OQRO

Oct 6, 2026, 7:59 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Jazz Pharmaceuticals plc

Issuer CIK

1232524

Ticker

JAZZ

Reporting person

Robert Iannone

Relationship

Officer

Officer title

EVP, Global Head of R&D & CMO

Security

Ordinary Shares

Table

Non-derivative (Table I)

Transaction date

Aug 27, 2026

Transaction code

Shares / units

2,916

Price per share

$137.12

Acquired / disposed

Acquired (A)

Shares owned after

142,607

Ownership form

Direct

Amendment

Footnotes from the filing

This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Around the same time

Neena M Patil (EVP & Chief Legal Officer) sold ~$289K of Jazz Pharmaceuticals

Scheduled in advanceFiled 3w ago

Renee D GalaPresident & CEO

Filed 4w ago

1,967Shares · @ $246.81

Traded Sep 8 · filed 3 days later

Routine share withholding; mechanical by default.

More Official record

Renee D Gala (President & CEO) sold ~$486K of Jazz Pharmaceuticals

Scheduled in advanceFiled 4w ago